share_log

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying

Vivani醫療和其他2只低於2美元的股票內部人員正在購買
Benzinga ·  08/02 19:41

The Dow Jones index closed lower by around 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週四收跌約500點。當內部人員買賣股票時，意味着他們對公司前景的信心或擔憂。對於有興趣購買低價股的投資者和交易員來說，可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。

Cyanotech

賽安諾科技

  • The Trade: Cyanotech Corporation (OTC:CYAN) Director Michael A / Davis bought a total of 10,000 shares at an average price of $0.77. To acquire these shares, it cost around $7,700.
  • What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.
  • What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.
  • 交易：賽安諾科技公司（OTC：CYAN）董事Michael A / Davis以平均價格0.77美元購買了總計1萬股。購買這些股票花費了約7700美元。
  • 近況：6月26日，Cyanotech報告稱，2024財年淨銷售額爲2,307.1萬美元，而2023財年爲2,317.8萬美元。
  • 賽安諾科技公司從微藻中提煉可用於營養補充劑市場的天然產品。

RENN Fund

renn fund

  • The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 1,164 shares at an average price of $1.79. To acquire these shares, it cost around $2,084.
  • What's Happening: RENN Fund shares gained around 7% over the past six months.
  • What RENN Fund Does: RENN Fund Inc is active in the financial services domain.
  • 交易：renn fund (NYSE:RCG)總裁兼首席執行官Murray Stahl以平均價格1.79美元購買了總計1164股。購買這些股票花費了約2084美元。
  • RENNS Fund股價在過去六個月內上漲了約7％。
  • RENNS Fund Inc在金融服務領域活躍。

Vivani Medical

Vivani 醫療

  • The Trade: Vivani Medical, Inc. (NASDAQ:VANI) Chief Business Officer Donald Dwyer acquired a total of 9,000 shares at an average price of $1.24. The insider spent around $11,120 to buy those shares. He also purchased 2,000 shares at $0.96.
  • What's Happening: Vivani Medical expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024.
  • What Vivani Medical Does: Vivani Medical Inc is a preclinical-stage biopharmaceutical company.
  • 交易：Vivani Medical, Inc. (NASDAQ:VANI)首席商務官Donald Dwyer以平均價格1.24美元購買了總計9000股。內部人員花費大約11,120美元購買了這些股票。他還以0.96美元購買了2000股。
  • 最新進展：Vivani Medical公司預計將於2024年第四季度在澳洲開始NPm-115項目的第一項臨床研究。
  • Vivani Medical Inc是一家處於臨床前階段的生物製藥公司。
  • Amazon, Apple And 3 Stocks To Watch Heading Into Friday
  • 週五關注的亞馬遜、蘋果和3只股票

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論